Chronic prehepatic portal hypertension in the rat: Is it a type of Metabolic Inflammatory Syndrome?

Lipids in Health and Disease

Volumn 7, Issue , 2008, Pages

  Sánchez Patán, Fernando ^a   Anchuelo, Raquel ^a   Aller, Maria Angeles ^a   Vara, Elena ^a   García, Cruz ^a   Nava, Maria Paz ^a   Arias, Jaime ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; LIPID BINDING PROTEIN; LIPOPROTEIN; PHOSPHOLIPID; SOMATOSTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; COLORIMETRY; CONTROL GROUP; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PORTAL HYPERTENSION; RAT; SOMATOSTATIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CHRONIC DISEASE; FEMALE; HYPERINSULINISM; LIVER CIRCULATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; CHOLESTEROL; CHRONIC DISEASE; FEMALE; HYPERINSULINISM; HYPERTENSION, PORTAL; LIVER CIRCULATION; MALE; METABOLIC SYNDROME X; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 40349094438     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-7-4     Document Type: Article

References (54)

1. Molecular and structural basis of portal hypertension. R Moreau D Lebrec, Clin Liver Dis 2006 10 445 457 10.1016/j.cld.2006.08.011 17162222
2. Current concepts on the pathophysiology of portal hypertension. A Rodriguez-Villarrupla M Fernandez J Bosch JC Garcia-Pagan, Ann Hepatol 2007 6 28 36 17297426
3. Portal hypertension: from pathophysiology to clinical practice. W Laleman L Van Landeghem A Wilmer J Fevery F Nevens, Liver Int 2005 25 1079 1090 10.1111/j.1478-3231.2005.01163.x 16343056
4. Measurement of portal-systemic shunting in the rat using γ-labeled microspheres. M Chojkier RJ Groszmann, Am J Physiol 1981 240 G371 G375 7235023
5. Animal models of portal hypertension. JG Abraldes M Pasarin J Garcia-Pagan, World J Gastroenterol 2006 12 6577 6584 17075968
6. Progressive hepatocytic fatty infiltration in rats with prehepatic portal hypertension. MJ Alonso MA Aller MT Corcuera MP Nava F Gomez A Angulo J Arias, Hepato-Gastroenterology 2005 52 541 546 15816474
7. Tumor necrosis factor-α, Interleukin 1β and Nitric Oxide: induction of liver megamitochondria in prehepatic portal hypertensive rats. I Prieto F Jimenez MA Aller MP Nava E Vara C Garcia J Arias, World J Surg 2005 29 903 908 10.1007/s00268-005-7757-5 15951934
8. Hepatic lipid metabolism changes in short- and long-term prehepatic portal hypertensive rats. MA Aller E Vara C Garcia MP Nava A Angulo F Sanchez-Patan A Calderon P Vergara J Arias, World J Gastroenterol 2006 12 6828 6834 17106932
9. Oxidative stress in portal hypertension-induced rats with particular emphasis on nitric oxide and trace metals. T Izzet K Osman U Ethem Y Nihat K Ramazan D Mustafa U Hafize KA Riza A Birsen G Habibe Sevala S Gonul, World J Gastroenterol 2005 11 3570 3573 15962377
10. Steatosis and portal hypertension. C Puoti L Bellis, Eur Rev Med Pharmacol Sci 2005 9 285 290 16231591
11. Neuro-immune-endocrine functional system and vascular pathology. MA Aller JL Arias L Lorente MP Nava HJ Duran J Arias, Med Hypotheses 2001 57 561 569 10.1054/mehy.2001.1408 11735311
12. Evolutive phases of the experimental prehepatic portal hypertension. MA Aller MP Nava M Duran E Alvarez JL Arias F Sanchez-Patan MA Llamas J Arias, J Gastroenterol Hepatol 2007 22 1127 1133 10.1111/j.1440-1746.2007.04876.x 17608859
13. Prehepatic portal hypertension produces increased mast cell density in the small bowel and in mesenteric lymph nodes in the rat. I Prieto MA Aller L Santamaria MP Nava R Madero JP Perez-Robledo J Arias, J Gastroenterol Hepatol 2005 20 1025 1031 15955210
14. Budesonide ameliorates early portal hypertension in the rat: possible antiexudative splanchnic action. M Vega De Ceniga F Valdes MA Aller MP Nava T Chivato J Arias, Inflammopharmacology 2003 11 211 222 10.1163/156856003322315569 15035804
15. Ketotifen reduces the splanchnic alterations in experimental prehepatic portal hypertension: involvement of the mast cells. F Sánchez- Patán MA Aller C Cuellar M Rodero C Corchera MP Nava F Gómez MD Blanco S Guerrero R Anchuelo E Mũiz MJ Alonso JM Teijón J Arias, Exper Toxicol Pathol
16. Portal hypertension produces an evolutive hepato-intestinal pro- and anti-inflammatory response in the rat. MD Palma MA Aller E Vara MP Nava C Garcia J Arias-Diaz JL Balibrea J Arias, Cytokine 2005 31 213 226 10.1016/j.cyto.2005. 04.008 15950486
17. 4 levels in short-term prehepatic portal hypertension in rats. G Monterde G Rodriguez-Fabian E Vara L Lopez JL Arias MA Aller J Arias, Dig Dis Sci 2000 45 1865 1871 10.1023/A:1005588918516 11052333
18. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. JA Solís Herruzo I Garcia Ruiz M Perez Carreras MT Mũoz Yagüe, Rev Esp Enferm Dig 2006 98 844 874 17198477
19. "Endocrine NAFLD" a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. A Lonardo C Carani N Carulli P Loria, J Hepatol 2006 44 1196 1207 10.1016/j.jhep.2006.03.005 16618516
20. NASH as part of the metabolic (insulin resistance) syndrome. G Marchesini E Burgianesi, Fatty Liver disease. NASH and related disorders Blackwell Publ. Ltd. Malden, Farell GC, George J, de la Mall F, McCullough AJ, 2005 55 65
21. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. JW Haukeland JK Damas Z Konopski EM Løberg T Haaland I Goverud PA Torjesen K Birkeland K BJøro P Aukrust, J Hepatol 2006 44 1167 1174 10.1016/j.jhep.2006.02.011 16618517
22. Role of inflammation in nonalcoholic steatohepatitis. S Choi AM Diehl, Curr Opin Gastroenterol 2005 21 702 707 10.1097/01.mog.0000182863.96421.47 16220049
23. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. JK Reddy S Rao, Am J Gastrointest Liver Physiol 2006 290 G852 G858 10.1152/ajpgi.00521.2005
24. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. AJ Sanyal, Nature Clin Pract Gastroenterol Hepatol 2005 2 46 53 10.1038/ncpgasthep0084
25. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. M Bradbury, Am J Physiol Gastrointest Liver Physiol 2006 290 G194 G198 10.1152/ajpgi.00413.2005 16407588
26. Lipid metabolism in hepatic steatosis. MW Bradbury PD Berk, Clin Liver Dis 2004 8 639 671 10.1016/j.cld.2004.04.005 15331068
27. Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats. MA Aller E Vara C Garcia MD Palma JL Arias MP Nava J Arias, Mediators Inflamm 2005 2005 101 111 16030393 10.1155/MI.2005.101
28. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. LA Videla R Rodrigo J Araya J Poniachik, TRENDS Mol Med 2006 12 555 558 10.1016/j.molmed.2006.10.001 17049925
29. Nonalcoholic fatty liver disease: Cytokine-Adipokine interplay and regulation of insulin resistance. H Tilg GS Hotamisligil, Gastroenterology 2006 131 934 945 10.1053/j.gastro.2006.05.054 16952562
30. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal hypertensive rats. JC Lopez-Talavera W Merrill RJ Groszmann, Gastroenterology 1985 108 761 767 10.1016/0016-5085(95)90449-2
31. Chronic and acute Portal Hypertension induce intestinal bacterial translocation to mesenteric lymph nodes in the rat. MP Nava MA Aller MA Llamas D Marquina J Arias, Acta Physiologica 2007 190 Supl 655
32. Metabolic syndrome-neurotrophic hypothesis. M Hristova L Aloe, Med Hypotheses 2006 66 545 549 10.1016/j.mehy.2005.08.055 16298496
33. Species differences in angiotensin II generation and degradation by mast cell chymases. Y Kunori Y Muroga M Iidaka H Mitsuhashi T Kamimura A Fukamizu, J Recept Signal Transduct Res 2005 25 35 44 10.1081/RRS-200054355 15960393
34. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. P Dandona S Dhinsa H Ghanim A Chaudhuri, J Human Hypert 2007 21 20 27 10.1038/sj.jhh.1002101
35. Fatty liver and the metabolic syndrome. BA Neuschwander-Tetri, Curr Opin Gastroenterol 2007 23 193 198 10.1097/MOG.0b013e32801421a9 17268250
36. Adipocytokines-Novel link between inflammation and vascular funcion? TJ Guzik D Mangalat R Korbut, J Physiol Pharmacol 2006 57 505 528 17229978
37. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Z Li S Yang H Liu PA Watking AB Moser C Desimone XY Song AM Diehl, Hepatology 2003 37 343 350 10.1053/jhep.2003.50048 12540784
38. Acute and "chronic" phase reaction -a mother of disease. S Bengmark, Clin Nutr 2004 23 1256 1266 10.1016/j.clnu.2004.07.016 15556248
39. Non-LPS target and actions of LPS binding protein (LBP). NWJ Schröder RR Schumann, J Endotoxin Res 2005 11 237 242 16176661
40. Lipoprotein metabolism in patients with severe sepsis. HJ Van Leeuwen EC Heezius GM Dallinga JA Van Strijp J Verhoef KP Van Kessel, Crit Care Med 2003 31 1359 1366 10.1097/01.CCM.0000059724.08290.51 12771603
41. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? A Chait CY Han JF Oram JW Heinecke, J Lipid Res 2005 46 389 403 10.1194/jlr.R400017-JLR200 15722558
42. The role of lipopolysaccharide-binding protein in modulating the innate immune response. J Zweigner RR Schumann JR Weber, Microbes Infect 2006 8 946 952 10.1016/j.micinf.2005.10.006 16483818
43. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. JFP Berbée LM Havekes PCN Rensen, J Endotoxin Res 2005 11 97 103 15949136
44. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. W El-Assaad J Buteau ML Peyot C Nolan R Roduit S Hardy E Joly G Dbaibo L Rosenberg M Prentki, Endocrinology 2003 144 4154 4163 10.1210/en.2003-0410 12933690
45. Metabolic flexibility. L Storlien ND Oakes DE Kelley, Proc Nutr Soc 2004 63 363 368 10.1079/PNS2004349 15294056
46. Transfer of maternal cholesterol to embryo and fetus in pregnant mice. S Yoshida Y Wada, J Lipid Res 2005 46 2168 2174 10.1194/jlr.M500096-JLR200 16061954
47. Proceedings: The development of an enzymatic technique for the assay of cholesterol in biological fluids. W Richmond, Clin Sci Mol Med 1974 46 6P 7P 4811879
48. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. P Fossati L Prencipe, Clin Chem 1982 28 2077 2080 6812986
49. Enzymatic determinations of cholesterol in high-density-lipoprotein fractions prepared by a precipitation technique. BW Steele DF Koehler MM Azar TP Blaszkowski K Kuba ME Dempsey, Clin Chem 1976 22 98 101 173479
50. Methods of Enzymatic Analysis. HU Bergmeyer E Bernt, New York Academic Press, Bergmeyer HU, 2 1974 1205 1212
51. Antigenic specificity of a new and potent somatostatin antiserum. J Tamarit-Rodriguez E Vara J Tamarit, Horm Metab Res 1985 17 623 625 2867965
52. 125I to high specific activity. JL Thorell BG Johansson, Biochem Biophys Acta 1971 251 363 369 11452877
53. Radioimmunoassay for GH-release inhibiting hormone. A Arimura H Sato DH Coy AV Scally, Proc Soc Exp Biol Med 1975 148 784 789 1129301
54. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. MM Bradford, Anal Biochem 1976 72 244 254 10.1016/0003-2697(76)90527-3 942051